Share Price and Basic Stock Data
Last Updated: June 20, 2025, 9:25 pm
| PEG Ratio | 0.00 |
|---|
Competitors of Panacea Biotec Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 141 Cr. | 100.0 | 247/84.3 | 27.3 | 41.7 | 0.00 % | 12.9 % | 9.75 % | 10.0 |
| MPS Pharmaa Ltd | 5.26 Cr. | 2.75 | 4.33/2.50 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 2,663 Cr. | 244 | 390/192 | 50.6 | 20.5 | 0.27 % | 45.0 % | 33.8 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 41.6 Cr. | 56.1 | 94.9/44.5 | 8.73 | 0.00 % | 41.5 % | 14.4 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 37.2 Cr. | 25.4 | 29.1/13.1 | 36.5 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 18,518.95 Cr | 1,150.69 | 93.48 | 194.72 | 0.31% | 16.67% | 15.20% | 6.18 |
Quarterly Result
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 140.73 | 110.70 | 105.12 | 115.20 | 128.93 | 129.19 | 143.02 | 150.50 | 136.46 | 115.72 | 147.35 | 163.49 | 132.53 |
| Expenses | 170.92 | 190.51 | 108.96 | 123.84 | 134.60 | 139.50 | 146.58 | 150.65 | 142.50 | 129.71 | 140.35 | 155.53 | 159.41 |
| Operating Profit | -30.19 | -79.81 | -3.84 | -8.64 | -5.67 | -10.31 | -3.56 | -0.15 | -6.04 | -13.99 | 7.00 | 7.96 | -26.88 |
| OPM % | -21.45% | -72.10% | -3.65% | -7.50% | -4.40% | -7.98% | -2.49% | -0.10% | -4.43% | -12.09% | 4.75% | 4.87% | -20.28% |
| Other Income | 1,680.26 | 39.95 | 38.22 | 41.71 | 34.44 | 33.82 | 6.00 | 8.46 | 13.55 | 6.54 | 7.42 | 6.39 | 36.30 |
| Interest | 30.66 | 1.25 | 1.18 | 0.96 | 1.05 | 1.00 | 0.91 | 0.85 | 0.82 | 0.87 | 0.98 | 0.99 | 1.04 |
| Depreciation | 11.15 | 10.05 | 9.89 | 9.67 | 9.51 | 9.48 | 9.31 | 9.11 | 8.81 | 8.73 | 8.68 | 8.98 | 8.42 |
| Profit before tax | 1,608.26 | -51.16 | 23.31 | 22.44 | 18.21 | 13.03 | -7.78 | -1.65 | -2.12 | -17.05 | 4.76 | 4.38 | -0.04 |
| Tax % | 23.06% | 9.73% | 32.65% | 13.68% | 169.63% | 15.73% | 6.56% | 33.33% | -6.13% | -6.86% | 1.05% | -1.37% | 4,875.00% |
| Net Profit | 1,237.47 | -56.14 | 15.70 | 19.37 | -12.68 | 10.98 | -8.29 | -2.20 | -1.99 | -15.88 | 4.71 | 4.44 | -1.99 |
| EPS in Rs | 201.86 | -9.16 | 2.56 | 3.16 | -2.07 | 1.79 | -1.35 | -0.37 | -0.32 | -2.59 | 0.78 | 0.74 | -0.31 |
Last Updated: May 31, 2025, 8:12 am
Below is a detailed analysis of the quarterly data for Panacea Biotec Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 132.53 Cr.. The value appears to be declining and may need further review. It has decreased from 163.49 Cr. (Dec 2024) to 132.53 Cr., marking a decrease of 30.96 Cr..
- For Expenses, as of Mar 2025, the value is 159.41 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 155.53 Cr. (Dec 2024) to 159.41 Cr., marking an increase of 3.88 Cr..
- For Operating Profit, as of Mar 2025, the value is -26.88 Cr.. The value appears to be declining and may need further review. It has decreased from 7.96 Cr. (Dec 2024) to -26.88 Cr., marking a decrease of 34.84 Cr..
- For OPM %, as of Mar 2025, the value is -20.28%. The value appears to be declining and may need further review. It has decreased from 4.87% (Dec 2024) to -20.28%, marking a decrease of 25.15%.
- For Other Income, as of Mar 2025, the value is 36.30 Cr.. The value appears strong and on an upward trend. It has increased from 6.39 Cr. (Dec 2024) to 36.30 Cr., marking an increase of 29.91 Cr..
- For Interest, as of Mar 2025, the value is 1.04 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.99 Cr. (Dec 2024) to 1.04 Cr., marking an increase of 0.05 Cr..
- For Depreciation, as of Mar 2025, the value is 8.42 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 8.98 Cr. (Dec 2024) to 8.42 Cr., marking a decrease of 0.56 Cr..
- For Profit before tax, as of Mar 2025, the value is -0.04 Cr.. The value appears to be declining and may need further review. It has decreased from 4.38 Cr. (Dec 2024) to -0.04 Cr., marking a decrease of 4.42 Cr..
- For Tax %, as of Mar 2025, the value is 4,875.00%. The value appears to be increasing, which may not be favorable. It has increased from -1.37% (Dec 2024) to 4,875.00%, marking an increase of 4,876.37%.
- For Net Profit, as of Mar 2025, the value is -1.99 Cr.. The value appears to be declining and may need further review. It has decreased from 4.44 Cr. (Dec 2024) to -1.99 Cr., marking a decrease of 6.43 Cr..
- For EPS in Rs, as of Mar 2025, the value is -0.31. The value appears to be declining and may need further review. It has decreased from 0.74 (Dec 2024) to -0.31, marking a decrease of 1.05.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 4:33 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 510 | 687 | 653 | 544 | 593 | 457 | 544 | 625 | 661 | 460 | 559 | 559 |
| Expenses | 582 | 643 | 541 | 505 | 509 | 591 | 490 | 548 | 674 | 558 | 579 | 585 |
| Operating Profit | -72 | 44 | 112 | 39 | 84 | -134 | 54 | 77 | -13 | -98 | -20 | -26 |
| OPM % | -14% | 6% | 17% | 7% | 14% | -29% | 10% | 12% | -2% | -21% | -4% | -5% |
| Other Income | 183 | 28 | 70 | 62 | 8 | 338 | -14 | 9 | 1,687 | 154 | 62 | 57 |
| Interest | 150 | 105 | 127 | 101 | 101 | 105 | 174 | 185 | 181 | 4 | 4 | 4 |
| Depreciation | 71 | 67 | 73 | 68 | 57 | 54 | 43 | 46 | 44 | 39 | 37 | 35 |
| Profit before tax | -111 | -99 | -19 | -67 | -66 | 45 | -178 | -146 | 1,449 | 13 | 1 | -8 |
| Tax % | 2% | 3% | 10% | -16% | 15% | 17% | 9% | 1% | 26% | 363% | 201% | 10% |
| Net Profit | -113 | -108 | -21 | -56 | -76 | 38 | -194 | -148 | 1,078 | -34 | -2 | -9 |
| EPS in Rs | -18.29 | -17.38 | -2.98 | -8.89 | -12.07 | 6.15 | -31.69 | -24.09 | 175.91 | -5.42 | -0.19 | -1.37 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 4.42% | 80.56% | -166.67% | -35.71% | 150.00% | -610.53% | 23.71% | 828.38% | -103.15% | 94.12% | -350.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 76.13% | -247.22% | 130.95% | 185.71% | -760.53% | 634.24% | 804.67% | -931.53% | 197.27% | -444.12% |
Panacea Biotec Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | 1% |
| 3 Years: | -5% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 12% |
| 3 Years: | 21% |
| TTM: | -58% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 17% |
| 3 Years: | 49% |
| 1 Year: | 218% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -6% |
| Last Year: | -5% |
Last Updated: Unknown
Balance Sheet
Last Updated: June 16, 2025, 11:35 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | 507 | 449 | 426 | 350 | 303 | 344 | 193 | -235 | 871 | 837 | 836 | 829 |
| Borrowings | 1,060 | 1,111 | 1,105 | 994 | 941 | 646 | 742 | 820 | 34 | 20 | 21 | 22 |
| Other Liabilities | 371 | 364 | 317 | 440 | 349 | 379 | 449 | 587 | 848 | 407 | 378 | 433 |
| Total Liabilities | 1,943 | 1,930 | 1,854 | 1,789 | 1,598 | 1,376 | 1,390 | 1,178 | 1,759 | 1,271 | 1,241 | 1,290 |
| Fixed Assets | 1,276 | 1,144 | 1,071 | 1,001 | 949 | 806 | 657 | 609 | 622 | 600 | 582 | 601 |
| CWIP | 172 | 155 | 161 | 30 | 40 | 23 | 24 | 34 | 17 | 42 | 102 | 94 |
| Investments | 16 | 15 | 9 | 7 | 7 | 5 | 6 | 0 | 5 | 13 | 40 | 3 |
| Other Assets | 479 | 616 | 614 | 750 | 602 | 542 | 703 | 534 | 1,114 | 615 | 517 | 592 |
| Total Assets | 1,943 | 1,930 | 1,854 | 1,789 | 1,598 | 1,376 | 1,390 | 1,178 | 1,759 | 1,271 | 1,241 | 1,290 |
Below is a detailed analysis of the balance sheet data for Panacea Biotec Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 6.00 Cr..
- For Reserves, as of Mar 2025, the value is 829.00 Cr.. The value appears to be declining and may need further review. It has decreased from 836.00 Cr. (Mar 2024) to 829.00 Cr., marking a decrease of 7.00 Cr..
- For Borrowings, as of Mar 2025, the value is 22.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 21.00 Cr. (Mar 2024) to 22.00 Cr., marking an increase of 1.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 433.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 378.00 Cr. (Mar 2024) to 433.00 Cr., marking an increase of 55.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 1,290.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,241.00 Cr. (Mar 2024) to 1,290.00 Cr., marking an increase of 49.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 601.00 Cr.. The value appears strong and on an upward trend. It has increased from 582.00 Cr. (Mar 2024) to 601.00 Cr., marking an increase of 19.00 Cr..
- For CWIP, as of Mar 2025, the value is 94.00 Cr.. The value appears to be declining and may need further review. It has decreased from 102.00 Cr. (Mar 2024) to 94.00 Cr., marking a decrease of 8.00 Cr..
- For Investments, as of Mar 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 40.00 Cr. (Mar 2024) to 3.00 Cr., marking a decrease of 37.00 Cr..
- For Other Assets, as of Mar 2025, the value is 592.00 Cr.. The value appears strong and on an upward trend. It has increased from 517.00 Cr. (Mar 2024) to 592.00 Cr., marking an increase of 75.00 Cr..
- For Total Assets, as of Mar 2025, the value is 1,290.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,241.00 Cr. (Mar 2024) to 1,290.00 Cr., marking an increase of 49.00 Cr..
Notably, the Reserves (829.00 Cr.) exceed the Borrowings (22.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -73.00 | 43.00 | 111.00 | -955.00 | -857.00 | -780.00 | -688.00 | -743.00 | -47.00 | -118.00 | -41.00 | -48.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 42 | 68 | 52 | 79 | 95 | 84 | 71 | 46 | 49 | 45 | 48 | 37 |
| Inventory Days | 371 | 375 | 404 | 516 | 770 | 651 | 173 | 344 | 311 | 296 | 292 | 282 |
| Days Payable | 243 | 430 | 272 | 318 | 607 | 540 | 572 | 463 | 440 | 327 | 256 | 244 |
| Cash Conversion Cycle | 170 | 13 | 184 | 278 | 259 | 195 | -328 | -73 | -80 | 14 | 83 | 76 |
| Working Capital Days | 92 | -113 | 31 | 134 | 82 | 6 | -307 | 97 | 6 | -229 | -5 | -2 |
| ROCE % | -8% | -8% | 0% | 4% | 2% | 3% | -16% | 4% | 5% | -6% | -10% | -4% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 117 | 0.02 | 0 | 117 | 2025-04-22 17:25:23 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | -1.37 | -0.19 | -5.43 | 175.98 | -24.11 |
| Diluted EPS (Rs.) | -1.37 | -0.19 | -5.43 | 175.98 | -24.11 |
| Cash EPS (Rs.) | 4.26 | 5.75 | 0.87 | 183.11 | -16.68 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 136.18 | 133.94 | 133.63 | 138.09 | -41.36 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 136.18 | 133.94 | 133.63 | 138.09 | -41.36 |
| Revenue From Operations / Share (Rs.) | 91.21 | 91.29 | 75.09 | 107.96 | 102.01 |
| PBDIT / Share (Rs.) | -0.85 | 0.93 | -7.56 | -0.47 | 14.14 |
| PBIT / Share (Rs.) | -6.54 | -5.06 | -13.95 | -7.60 | 6.70 |
| PBT / Share (Rs.) | -1.30 | 0.24 | 2.09 | 236.54 | -23.56 |
| Net Profit / Share (Rs.) | -1.42 | -0.24 | -5.51 | 175.98 | -24.12 |
| NP After MI And SOA / Share (Rs.) | -1.37 | -0.19 | -5.43 | 175.98 | -24.11 |
| PBDIT Margin (%) | -0.93 | 1.02 | -10.06 | -0.43 | 13.86 |
| PBIT Margin (%) | -7.16 | -5.53 | -18.57 | -7.04 | 6.56 |
| PBT Margin (%) | -1.42 | 0.26 | 2.78 | 219.10 | -23.09 |
| Net Profit Margin (%) | -1.55 | -0.26 | -7.33 | 163.01 | -23.64 |
| NP After MI And SOA Margin (%) | -1.49 | -0.20 | -7.22 | 163.01 | -23.63 |
| Return on Networth / Equity (%) | -1.00 | -0.14 | -4.04 | 126.99 | 0.00 |
| Return on Capital Employeed (%) | -4.34 | -3.32 | -9.09 | -4.75 | 5.44 |
| Return On Assets (%) | -0.64 | -0.09 | -2.61 | 60.47 | -12.52 |
| Long Term Debt / Equity (X) | 0.02 | 0.01 | 0.01 | 0.03 | -2.92 |
| Total Debt / Equity (X) | 0.02 | 0.01 | 0.01 | 0.03 | -2.92 |
| Asset Turnover Ratio (%) | 0.44 | 0.44 | 0.30 | 0.24 | 0.31 |
| Current Ratio (X) | 1.49 | 1.57 | 1.71 | 1.30 | 1.20 |
| Quick Ratio (X) | 0.90 | 0.99 | 1.10 | 1.03 | 0.79 |
| Inventory Turnover Ratio (X) | 1.09 | 1.11 | 1.02 | 1.14 | 0.58 |
| Interest Coverage Ratio (X) | -1.35 | 1.60 | -10.43 | -0.01 | 0.46 |
| Interest Coverage Ratio (Post Tax) (X) | -10.52 | -9.48 | -29.74 | -2.31 | 0.21 |
| Enterprise Value (Cr.) | 2612.25 | 620.65 | 454.38 | 355.93 | 1682.86 |
| EV / Net Operating Revenue (X) | 4.67 | 1.11 | 0.98 | 0.53 | 2.69 |
| EV / EBITDA (X) | -497.57 | 108.22 | -9.81 | -122.86 | 19.43 |
| MarketCap / Net Operating Revenue (X) | 4.83 | 1.33 | 1.44 | 1.37 | 1.74 |
| Price / BV (X) | 3.24 | 0.90 | 0.80 | 1.07 | -4.34 |
| Price / Net Operating Revenue (X) | 4.83 | 1.33 | 1.44 | 1.37 | 1.74 |
| EarningsYield | 0.00 | 0.00 | -0.05 | 1.19 | -0.13 |
After reviewing the key financial ratios for Panacea Biotec Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -1.37. This value is below the healthy minimum of 5. It has decreased from -0.19 (Mar 24) to -1.37, marking a decrease of 1.18.
- For Diluted EPS (Rs.), as of Mar 25, the value is -1.37. This value is below the healthy minimum of 5. It has decreased from -0.19 (Mar 24) to -1.37, marking a decrease of 1.18.
- For Cash EPS (Rs.), as of Mar 25, the value is 4.26. This value is within the healthy range. It has decreased from 5.75 (Mar 24) to 4.26, marking a decrease of 1.49.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 136.18. It has increased from 133.94 (Mar 24) to 136.18, marking an increase of 2.24.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 136.18. It has increased from 133.94 (Mar 24) to 136.18, marking an increase of 2.24.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 91.21. It has decreased from 91.29 (Mar 24) to 91.21, marking a decrease of 0.08.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.85. This value is below the healthy minimum of 2. It has decreased from 0.93 (Mar 24) to -0.85, marking a decrease of 1.78.
- For PBIT / Share (Rs.), as of Mar 25, the value is -6.54. This value is below the healthy minimum of 0. It has decreased from -5.06 (Mar 24) to -6.54, marking a decrease of 1.48.
- For PBT / Share (Rs.), as of Mar 25, the value is -1.30. This value is below the healthy minimum of 0. It has decreased from 0.24 (Mar 24) to -1.30, marking a decrease of 1.54.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -1.42. This value is below the healthy minimum of 2. It has decreased from -0.24 (Mar 24) to -1.42, marking a decrease of 1.18.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -1.37. This value is below the healthy minimum of 2. It has decreased from -0.19 (Mar 24) to -1.37, marking a decrease of 1.18.
- For PBDIT Margin (%), as of Mar 25, the value is -0.93. This value is below the healthy minimum of 10. It has decreased from 1.02 (Mar 24) to -0.93, marking a decrease of 1.95.
- For PBIT Margin (%), as of Mar 25, the value is -7.16. This value is below the healthy minimum of 10. It has decreased from -5.53 (Mar 24) to -7.16, marking a decrease of 1.63.
- For PBT Margin (%), as of Mar 25, the value is -1.42. This value is below the healthy minimum of 10. It has decreased from 0.26 (Mar 24) to -1.42, marking a decrease of 1.68.
- For Net Profit Margin (%), as of Mar 25, the value is -1.55. This value is below the healthy minimum of 5. It has decreased from -0.26 (Mar 24) to -1.55, marking a decrease of 1.29.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -1.49. This value is below the healthy minimum of 8. It has decreased from -0.20 (Mar 24) to -1.49, marking a decrease of 1.29.
- For Return on Networth / Equity (%), as of Mar 25, the value is -1.00. This value is below the healthy minimum of 15. It has decreased from -0.14 (Mar 24) to -1.00, marking a decrease of 0.86.
- For Return on Capital Employeed (%), as of Mar 25, the value is -4.34. This value is below the healthy minimum of 10. It has decreased from -3.32 (Mar 24) to -4.34, marking a decrease of 1.02.
- For Return On Assets (%), as of Mar 25, the value is -0.64. This value is below the healthy minimum of 5. It has decreased from -0.09 (Mar 24) to -0.64, marking a decrease of 0.55.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.44. There is no change compared to the previous period (Mar 24) which recorded 0.44.
- For Current Ratio (X), as of Mar 25, the value is 1.49. This value is below the healthy minimum of 1.5. It has decreased from 1.57 (Mar 24) to 1.49, marking a decrease of 0.08.
- For Quick Ratio (X), as of Mar 25, the value is 0.90. This value is below the healthy minimum of 1. It has decreased from 0.99 (Mar 24) to 0.90, marking a decrease of 0.09.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 4. It has decreased from 1.11 (Mar 24) to 1.09, marking a decrease of 0.02.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -1.35. This value is below the healthy minimum of 3. It has decreased from 1.60 (Mar 24) to -1.35, marking a decrease of 2.95.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -10.52. This value is below the healthy minimum of 3. It has decreased from -9.48 (Mar 24) to -10.52, marking a decrease of 1.04.
- For Enterprise Value (Cr.), as of Mar 25, the value is 2,612.25. It has increased from 620.65 (Mar 24) to 2,612.25, marking an increase of 1,991.60.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.67. This value exceeds the healthy maximum of 3. It has increased from 1.11 (Mar 24) to 4.67, marking an increase of 3.56.
- For EV / EBITDA (X), as of Mar 25, the value is -497.57. This value is below the healthy minimum of 5. It has decreased from 108.22 (Mar 24) to -497.57, marking a decrease of 605.79.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.83. This value exceeds the healthy maximum of 3. It has increased from 1.33 (Mar 24) to 4.83, marking an increase of 3.50.
- For Price / BV (X), as of Mar 25, the value is 3.24. This value exceeds the healthy maximum of 3. It has increased from 0.90 (Mar 24) to 3.24, marking an increase of 2.34.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.83. This value exceeds the healthy maximum of 3. It has increased from 1.33 (Mar 24) to 4.83, marking an increase of 3.50.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Panacea Biotec Ltd:
- Net Profit Margin: -1.55%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -4.34% (Industry Average ROCE: 16.67%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -1% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -10.52
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.9
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 93.48)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -1.55%
About the Company - Qualitative Analysis
Panacea Biotec Ltd. is a Public Limited Listed company incorporated on 02/02/1984 and has its registered office in the State of Punjab, India. Company's Corporate Identification Number(CIN) is L33117PB1984PLC022350 and registration number is 022350. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 309.85 Cr. and Equity Capital is Rs. 6.13 Cr. for the Year ended 31/03/2025.
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Ambala-Chandigarh Highway, Lalru Punjab 140501 | companysec@panaceabiotec.com http://www.panaceabiotec.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Rajesh Jain | Chairman & Managing Director |
| Mr. Sandeep Jain | Joint Managing Director |
| Mr. Ankesh Jain | Whole Time Director |
| Mrs. Ambika Sharma | Non Executive Director |
| Mr. N N Khamitkar | Non Executive Director |
| Mr. Mukul Gupta | Non Executive Director |
| Mr. Narotam Kumar Juneja | Non Executive Director |
| Mr. K M Lal | Non Executive Director |
| Mrs. Manjula Upadhyay | Non Executive Director |
| Mr. Bhupinder Singh | Non Executive Director |
FAQ
What is the intrinsic value of Panacea Biotec Ltd?
Panacea Biotec Ltd's intrinsic value (as of 20 June 2025) is ₹83.73 — 80.35% lower the current market price of 426.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 2,614 Cr. market cap, FY2025-2026 high/low of ₹582/130, reserves of 829 Cr, and liabilities of 1,290 Cr.
What is the Market Cap of Panacea Biotec Ltd?
The Market Cap of Panacea Biotec Ltd is 2,614 Cr..
What is the current Stock Price of Panacea Biotec Ltd as on 20 June 2025?
The current stock price of Panacea Biotec Ltd as on 20 June 2025 is 426.
What is the High / Low of Panacea Biotec Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Panacea Biotec Ltd stocks is ₹582/130.
What is the Stock P/E of Panacea Biotec Ltd?
The Stock P/E of Panacea Biotec Ltd is .
What is the Book Value of Panacea Biotec Ltd?
The Book Value of Panacea Biotec Ltd is 136.
What is the Dividend Yield of Panacea Biotec Ltd?
The Dividend Yield of Panacea Biotec Ltd is 0.00 %.
What is the ROCE of Panacea Biotec Ltd?
The ROCE of Panacea Biotec Ltd is 4.68 %.
What is the ROE of Panacea Biotec Ltd?
The ROE of Panacea Biotec Ltd is 5.03 %.
What is the Face Value of Panacea Biotec Ltd?
The Face Value of Panacea Biotec Ltd is 1.00.